Henrik S. Rassmussen net worth and biography

Henrik Rassmussen Biography and Net Worth

Insider of Allakos

Dr. Henrik Sandvad Rasmussen M.D. Ph.D serves as Chief Medical Officer of the Company. From October 2012 through June 2016, Dr. Rasmussen served as Chief Medical Officer at ZS Pharma, a biotechnology company. From August 2009 to October 2012 and from June 2015 to June 2017, Dr. Rasmussen served as President and Chief Executive Officer of Rasmussen Biotech and Pharma Consulting. Dr. Rasmussen also previously held the positions of Corporate Vice President and Head of Clinical Development and Medical and Regulatory Affairs at Novo Nordisk. He also previously served as Chief Medical Officer for Nabi Biopharmaceuticals and Genvec. He was also previously Vice President for Clinical Research and Senior Vice President for Clinical Research and Regulatory Affairs at British Biotech and International Clinical Project Manager and Global Study Director for cardiovascular drug development at Pfizer Central Research. Dr. Rasmussen has led numerous global development programs and regulatory filings worldwide, including NDAs. Dr. Rasmussen received his M.D. and Ph.D. from the University of Copenhagen in Denmark and is trained in internal medicine and cardiology.

How do I contact Henrik S. Rassmussen?: The corporate mailing address for Dr. Rassmussen and other Allakos executives is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. Allakos can also be reached via phone at (650) 597-5002 and via email at ir@allakos.com. Learn More on Henrik S. Rassmussen's contact information.
Has Henrik S. Rassmussen been buying or selling shares of Allakos?: Henrik S. Rassmussen has not been actively trading shares of Allakos during the past quarter. Learn More on Henrik S. Rassmussen's trading history.
Who are Allakos' active insiders?: Allakos' insider roster includes Robert Alexander (CEO), Peter Hudson (Major Shareholder), Steven James (Director), Daniel Janney (Director), Robert More (Major Shareholder), Henrik Rassmussen (Insider), and Adam Tomasi (COO). Learn More on Allakos' active insiders.
Are insiders buying or selling shares of Allakos?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 87,064 shares worth more than $87,934.64. The most recent insider tranaction occured on June, 28th when CFO Harlan Baird Radford sold 87,064 shares worth more than $87,934.64. Insiders at Allakos own 16.1% of the company. Learn More about insider trades at Allakos.
Information on this page was last updated on 6/28/2024.

Henrik S. Rassmussen Insider Trading History at Allakos

Henrik S. Rassmussen Buying and Selling Activity at Allakos

Allakos Company Overview

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Today's Range

Now: $0.23

$0.22

$0.24

50 Day Range

MA: $0.34

$0.23

$1.21

2 Week Range

Now: $0.23

$0.22

$1.56

Volume

734,744 shs

Average Volume

1,003,535 shs

Market Capitalization

$20.76 million

P/E Ratio

N/A

Dividend Yield